NTLA Latest Press Releases

-- November 5, 2026 --

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates Globe Newswire 8:00 AM

-- November 4, 2026 --

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) Globe Newswire 8:00 AM

-- November 3, 2026 --

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations Globe Newswire 8:00 AM

-- October 29, 2026 --

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 Globe Newswire 8:00 AM

-- October 28, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:15 PM

-- October 13, 2026 --

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer Globe Newswire 7:30 AM

-- October 2, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 8, 2026 --

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) Globe Newswire 8:00 AM

-- September 4, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million Globe Newswire 8:50 AM

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference Globe Newswire 8:00 AM

-- August 7, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 6, 2026 --

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Globe Newswire 7:00 AM

-- July 30, 2026 --

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates Globe Newswire 8:00 AM

-- July 6, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 13, 2026 --

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Globe Newswire 7:30 AM

-- June 5, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes